tiprankstipranks
Medpace Holdings (MEDP)
NASDAQ:MEDP

Medpace Holdings (MEDP) Stock Price & Analysis

489 Followers

MEDP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$227.21 - $437.39
Previous Close$404.42
Volume119.94K
Average Volume (3M)213.79K
Market Cap
$12.49B
Enterprise Value$12.69B
Total Cash (Recent Filing)$39.14M
Total Debt (Recent Filing)$194.39M
Price to Earnings (P/E)41.2
Beta1.71
Jul 22, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.81
Shares Outstanding30,983,399
10 Day Avg. Volume181,991
30 Day Avg. Volume213,792
Standard Deviation0.12
R-Squared0.36
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-40.61
Price to Sales (P/S)8.57
Price to Cash Flow (P/CF)37.90
P/FCF Ratio41.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.58
Enterprise Value/Gross Profit29.33
Enterprise Value/Ebitda37.66
Forecast
Price Target Upside11.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say
Debt ManagementMEDP has historically maintained very low debt relative to peers, and currently the company has no debt outstanding.
Financial PerformanceMEDP boasts industry-leading revenue, EBITDA, and EPS growth over the past five years, compared to the peer averages.
Market PositionIndustry checks were overwhelmingly positive on MEDP.
Bears Say
Backlog ConversionBacklog conversion dropped sequentially and year-over-year.
BookingsBookings could have been better, but this doesn’t concern the company.
HeadcountHeadcount was below model expectations and hiring targets were lowered.
---

Financials

Annual

Ownership Overview

32.95%27.66%19.78%19.61%
32.95% Insiders
19.78% Other Institutional Investors
19.61% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

MEDP FAQ

What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $227.21 and its highest was $437.39 in the past 12 months.
    What is Medpace Holdings’s market cap?
    Currently, no data Available
    When is Medpace Holdings’s upcoming earnings report date?
    Medpace Holdings’s upcoming earnings report date is Jul 22, 2024 which is in 19 days.
      How were Medpace Holdings’s earnings last quarter?
      Medpace Holdings released its earnings results on Apr 22, 2024. The company reported $3.2 earnings per share for the quarter, beating the consensus estimate of $2.466 by $0.734.
        Is Medpace Holdings overvalued?
        According to Wall Street analysts Medpace Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Medpace Holdings pay dividends?
          Medpace Holdings does not currently pay dividends.
          What is Medpace Holdings’s EPS estimate?
          Medpace Holdings’s EPS estimate is $2.53.
            How many shares outstanding does Medpace Holdings have?
            Medpace Holdings has 30,983,398 shares outstanding.
              What happened to Medpace Holdings’s price movement after its last earnings report?
              Medpace Holdings reported an EPS of $3.2 in its last earnings report, beating expectations of $2.466. Following the earnings report the stock price went up 8.21%.
                Which hedge fund is a major shareholder of Medpace Holdings?
                Among the largest hedge funds holding Medpace Holdings’s share is Fisher Asset Management LLC. It holds Medpace Holdings’s shares valued at 48M.
                  ---

                  Company Description

                  Medpace Holdings

                  Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.
                  ---

                  MEDP Company Deck

                  ---

                  MEDP Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  MEDP Revenue Breakdown

                  31.13%31.13%19.98%10.27%8.66%29.95%
                  31.13% Oncology
                  19.98% Metabolic
                  10.27% Cardiology
                  8.66% AVAI
                  29.95% Other
                  tipranks
                  ---

                  MEDP Stock 12 Month Forecast

                  Average Price Target

                  $451.00
                  ▲(11.89% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"234":"$234","465":"$465","291.75":"$291.8","349.5":"$349.5","407.25":"$407.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":464,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$464.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":451,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$451.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$435.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[234,291.75,349.5,407.25,465],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.19,406.02153846153846,410.8530769230769,415.68461538461537,420.5161538461538,425.3476923076923,430.1792307692308,435.01076923076926,439.8423076923077,444.67384615384617,449.5053846153846,454.3369230769231,459.16846153846154,{"y":464,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.19,405.02153846153846,408.8530769230769,412.68461538461537,416.5161538461538,420.3476923076923,424.1792307692308,428.01076923076926,431.8423076923077,435.67384615384617,439.5053846153846,443.3369230769231,447.16846153846154,{"y":451,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.19,403.79076923076923,406.39153846153846,408.9923076923077,411.5930769230769,414.19384615384615,416.7946153846154,419.3953846153846,421.99615384615385,424.5969230769231,427.1976923076923,429.79846153846154,432.39923076923077,{"y":435,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":240.17,"date":1688083200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.53,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":258.75,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.5,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":246.08,"date":1696550400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":274.21,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.41,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.97,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":295.63,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":400.75,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.57,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.19,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  NovoCure
                  Bristol-Myers Squibb
                  Incyte
                  Qiagen

                  Best Analysts Covering MEDP

                  1 Year
                  Eric ColdwellRobert W. Baird
                  1 Year Success Rate
                  3/5 ratings generated profit
                  60%
                  1 Year Average Return
                  +18.06%
                  upgraded a buy rating 2 months ago
                  Copying Eric Coldwell's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +18.06% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis